Celera Corporation
San Jose, CA, US· latest recorded location
Celera Corporation is named on 94 US grants and 171 published applications in this corpus. Its most frequent classification is C12Q (Measuring or testing processes involving enzymes, nucleic acids or microorganisms).
- Granted patents
- 94
- Published applications
- 171
- Inventors
- 88
- Granted in 2026 so far
- 0
- Most recent grant
- 12 Nov 2024
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2008 | 1 | 1 |
| 2009 | 7 | 16 |
| 2010 | 15 | 13 |
| 2011 | 11 | 9 |
| 2012 | 7 | 12 |
| 2013 | 5 | 14 |
| 2014 | 4 | 22 |
| 2015 | 2 | 7 |
| 2016 | 1 | 15 |
| 2017 | 1 | 11 |
| 2018 | 4 | 7 |
| 2019 | 3 | 9 |
| 2020 | 5 | 13 |
| 2021 | 9 | 8 |
| 2022 | 5 | 3 |
| 2023 | 7 | 9 |
| 2024 | 7 | 1 |
| 2025 | 0 | 1 |
By publication year.
Technology areas
Share of 265 documents
- C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms228
- A61PTherapeutic uses of medicines191
- G01NInvestigating or analysing materials by determining their chemical or physical properties137
- A61KMedicines and medical preparations108
- C07KPeptides92
- C12NMicroorganisms or enzymes61
- Y10TTechnical subjects covered by former us classification43
- G06FComputing and data processing22
- C12YEnzymes15
- G16BBioinformatics, i.e. information and communication technology [ict] specially adapted for genetic or10
Recent patents
- Automated circuit generation12 Nov 2024US 12,141,511 B2
- Automated circuit generation17 Sep 2024US 12,093,618 B2
- Automated circuit generation17 Sep 2024US 12,093,619 B2
- Genetic polymorphisms associated with stroke, methods of detection and uses thereof3 Sep 2024US 12,077,825 B2
- Automated circuit generation3 Sep 2024US 12,079,555 B2
- Automated circuit generation9 Jan 2025US 2025/0013812 A1
- Automated circuit generation5 Dec 2024US 2024/0403524 A1
- Automated circuit generation19 Oct 2023US 2023/0334207 A1
- Automated circuit generation7 Sep 2023US 2023/0281367 A1
- Automated circuit generation31 Aug 2023US 2023/0274057 A1
Most cited
By later US patents
- Breast disease targets and uses thereof76US 7,842,467 B12010
- Lung disease targets and uses thereof65US 7,807,392 B12010
- Kidney disease targets and uses thereof54US 7,608,413 B12009
- Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof24US 7,482,117 B22009
- Colon disease targets and uses thereof24US 7,842,466 B12010